Side-by-side comparison of AI visibility scores, market position, and capabilities
Metabolic health company delivering one-year GLP-1 programs with semaglutide or tirzepatide plus behavioral coaching, nutrition, and activity guidance via physician-supervised telehealth.
Calibrate is a metabolic health company that delivers a one-year weight loss program combining GLP-1 receptor agonist medications — including semaglutide and tirzepatide — with behavioral coaching, food education, sleep guidance, and activity programming through a telehealth platform. The program's clinical foundation differentiates it from consumer weight loss apps and traditional diet programs by centering medication management under physician supervision as the primary intervention, with lifestyle coaching structured to support long-term habit change alongside pharmaceutical treatment. Calibrate's approach reflects the clinical consensus that obesity is a chronic metabolic disease requiring medical treatment rather than a lifestyle choice addressable through willpower alone.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.